NYSE$TEVA

Teva Pharmaceutical Industries ADR · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Teva's financial performance was impacted by rising costs and unfavorable portfolio mix, but saw growth in key regions and innovative products.

Teva Pharmaceutical Industries Ltd. reported flat revenues of $3.661 billion for Q1 2023 compared to Q1 2022. However, in local currency terms, revenues increased by 4%. The company reported a GAAP loss per share of $0.18 and a non-GAAP diluted EPS of $0.40. Teva reaffirms its 2023 non-GAAP outlook.

  • Revenues reached $3.7 billion, a 4% increase in local currency terms.
  • Solid growth experienced across all regions, including Europe (9%), International Markets (8%), and North America (2%).
  • Innovative brands performed well, with AUSTEDO growing 10% year-over-year and AJOVY growing 35% across all regions in local currency.
  • AUSTEDO XR and UZEDY received recent approvals, with UZEDY expected to be available in the U.S. in the coming weeks.

Headline financials

Total Revenue

$3.66B

Previous: $3.66B+0.0%
EPS (adj)

$0.40

Previous: $0.55-27.3%
Adjusted EBITDA

$899M

Previous: $1.14B-20.8%
Non-GAAP Operating Income

$785M

No prior period
Non-GAAP Gross Profit Margin

49.1%

No prior period
Capital Expenditures

-$139M

Previous: -$157M+11.5%
Free Cash Flow

-$344M

Previous: -$1.11B+69.1%
Net Income

-$205M

Previous: -$955M+78.5%
Operating Income

$2M

Previous: -$713M+100.3%
Gross Profit

$1.58B

Previous: $1.74B-9.1%
Cash & Equivalents

$2.14B

Previous: $2.18B-1.5%
Total Assets

$43.5B

Previous: $47.1B-7.7%
Stock-Based Comp

$32M

Previous: $24M+33.3%

Revenue & EPS history

Teva · Revenue · Quarterly

$3.66B

Q1 2023+0%vs Q1 2022
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Teva · $1.9B total across 3 segments · Q1 2023

  • Europe
    $1.18B+2.4%
  • International Markets
    $492M+0.0%
  • Other Activities
    $219M-20.4%

Forward guidance

Teva reaffirms its full year 2023 business outlook, which includes revenue, Adjusted EBITDA, Non-GAAP diluted EPS, and free cash flow.

Tailwinds

  • Revenues of $14.8 - $15.4 billion
  • Adjusted EBITDA of $4.5 - $4.9 billion
  • Non-GAAP diluted EPS of $2.25 - $2.55
  • Free cash flow of $1.7 - $2.1 billion
  • Gross profit margin to improve in the coming quarters due to improved portfolio mix driven by our innovative products, namely AUSTEDO®, AJOVY® and UZEDY™, as well as by lower COGS, driven by supply chain enhancements and easing of certain elements of inflationary pressure.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+0.3%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+0.7%

Avg return

30 days after

51%

38 / 74 earnings

Positive

+27.1%

Q2 2022

Best reaction

-34.1%

Q2 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.1%+11.9%+11.7%
Q4 2025+2.1%+9.2%+4.1%
Q3 2025+20.4%+18.6%+39.1%
Q2 2025+1.8%-5.1%+11.1%
Q1 2025+8.9%+11.4%+10.2%
Q4 2024-13.9%-19.4%-23.5%
Q3 2024-6.8%-7.5%-7.7%
Q2 2024+6.9%+1.6%+15.0%
Q1 2024+14.7%+21.0%+20.6%
Q4 2023+6.2%+5.5%+15.1%
Q3 2023-3.0%-2.4%+8.6%
Q2 2023+15.4%+16.2%+18.7%
Q1 2023-9.8%-11.3%-19.5%
Q4 2022-9.8%-5.4%-16.3%
Q3 2022-3.3%+3.7%-1.1%
Q2 2022+27.1%+30.5%+37.6%
Q1 2022-2.3%-8.1%+11.6%
Q4 2021+6.3%+2.8%-9.8%
Q3 2021-7.0%-1.7%-9.6%
Q2 2021+8.6%+10.4%+4.8%
Q1 2021+2.6%+4.2%+0.3%
Q4 2020-11.8%-13.2%-15.8%
Q3 2020-1.0%+4.5%+11.6%
Q2 2020+3.0%+0.6%-22.1%
Q1 2020+7.7%+9.0%+22.5%
Q4 2019+1.9%-0.9%-31.9%
Q3 2019+14.8%+18.6%+22.5%
Q2 2019+3.3%-0.6%-0.7%
Q1 2019-0.3%-4.1%-43.2%
Q4 2018-9.6%-6.0%-13.7%
Q3 2018+13.1%+15.6%+7.8%
Q2 2018-7.1%-2.5%-4.0%
Q1 2018-4.1%+1.6%+17.7%
Q4 2017-10.7%-11.2%-8.0%
Q3 2017-18.7%-16.6%+8.8%
Q2 2017-34.1%-16.2%-39.4%
Q1 2017+1.7%+1.3%-3.6%
Q4 2016+8.4%+9.4%+6.7%
Q3 2016-7.2%-6.0%-10.5%
Q2 2016+1.2%-6.2%-8.8%
Q1 2016+5.2%+1.7%+10.8%
Q4 2015-2.0%
Q3 2015-5.1%
Q2 2015-2.6%
Q1 2015+0.1%
Q3 2014+3.6%
Q4 2014+2.0%
Q2 2014-1.6%
Q1 2014+2.0%
Q4 2013-1.9%
Q3 2013-1.5%
Q2 2013-2.0%
Q1 2013+1.0%
Q4 2012+1.4%
Q3 2012+2.6%
Q2 2012-3.3%
Q1 2012-5.4%
Q4 2011+2.5%
Q3 2011+7.0%
Q2 2011+1.9%
Q1 2011+5.6%
Q4 2010+0.4%
Q3 2010+0.3%
Q2 2010-3.4%
Q1 2010+0.9%
Q4 2007+1.2%
Q4 2009+1.2%
Q3 2008-1.4%
Q3 2009-1.4%
Q2 2008-0.8%
Q2 2009-0.8%
Q1 2009-0.6%
Q1 2008-0.6%
Q4 2008-0.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro